A Severe Case of Cutaneous Adverse Drug Reaction Secondary to a Novice Drug: Idelalisib

• Hoofdauteurs: Joseph Gabriel Gabriel MD (Auteur), Aaysha Kapila MD (Auteur), Alexei Gonzalez-Estrada MD (Auteur)
• Formaat: Boek
• Gepubliceerd in: SAGE Publishing, 2017-05-01T00:00:00Z.
• Onderwerpen: article
• Online toegang: Connect to this object online.

Phosphatidylinositol 3-kinase δ (PIK3δ) is a tyrosine kinase essential for B cell survival, making it an important target in the treatment of chronic lymphocytic leukemia. Idelalisib is an inhibitor of PIK3δ demonstrating initial success in disease response, but is now shown to have a decreased over...